Director Margaret M FitzPatrick purchases 8,610 shares of ANTX at $1.18; company reports $-10.6M net loss.
FitzPatrick, a director, purchased 8,610 shares at $1.18 on 2025-05-28, representing her first holding in ANTX. The company reported a net income of $-10,649,000.00 and operates at a market cap of $36,512,621.20, indicating a pre-revenue or early-stage biotech profile typical of AN2 Therapeutics. The stock currently trades at $1.21, down 59.1% from its 52-week high of $2.96, suggesting the purchase occurred during a significant drawdown. This insider buy by a director during a period of substantial losses and depressed valuation relative to the 52-week range provides a data point on insider willingness to accumulate at lower prices, though the transaction size and dollar value remain modest relative to market capitalization.